Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 264

1.

Recommendations for benefit-risk assessment methodologies and visual representations.

Hughes D, Waddingham E, Mt-Isa S, Goginsky A, Chan E, Downey GF, Hallgreen CE, Hockley KS, Juhaeri J, Lieftucht A, Metcalf MA, Noel RA, Phillips LD, Ashby D, Micaleff A; PROTECT Benefit-Risk Group.

Pharmacoepidemiol Drug Saf. 2016 Jan 22. doi: 10.1002/pds.3958. [Epub ahead of print]

PMID:
26800458
2.

Increased prevalence of eosinophilia in a hemodialysis population: Longitudinal and case control studies.

Hildebrand S, Corbett R, Duncan N, Ashby D.

Hemodial Int. 2016 Jan 7. doi: 10.1111/hdi.12395. [Epub ahead of print]

PMID:
26749440
3.

Oral steroids for long-term use in cystic fibrosis.

Cheng K, Ashby D, Smyth RL.

Cochrane Database Syst Rev. 2015 Dec 9;12:CD000407. doi: 10.1002/14651858.CD000407.pub4. Review.

PMID:
26649765
4.

Literature review of visual representation of the results of benefit-risk assessments of medicinal products.

Hallgreen CE, Mt-Isa S, Lieftucht A, Phillips LD, Hughes D, Talbot S, Asiimwe A, Downey G, Genov G, Hermann R, Noel R, Peters R, Micaleff A, Tzoulaki I, Ashby D; PROTECT Benefit-Risk group.

Pharmacoepidemiol Drug Saf. 2015 Nov 2. doi: 10.1002/pds.3880. [Epub ahead of print] Review.

PMID:
26521865
5.

Manifestation of West Nile Encephalitis in Infancy.

Appavu B, Ashby D, Condie J.

J Pediatric Infect Dis Soc. 2015 Dec;4(4):e166-8. doi: 10.1093/jpids/piv072. Epub 2015 Oct 14. No abstract available.

PMID:
26501475
6.

Structured Frameworks to Increase the Transparency of the Assessment of Benefits and Risks of Medicines: Current Status and Possible Future Directions.

Pignatti F, Ashby D, Brass EP, Eichler HG, Frey P, Hillege HL, Hori A, Levitan B, Liberti L, Löfstedt RE, McAuslane N, Micaleff A, Noel RA, Postmus D, Renn O, Sabourin BJ, Salmonson T, Walker S.

Clin Pharmacol Ther. 2015 Nov;98(5):522-33. doi: 10.1002/cpt.203. Epub 2015 Sep 11. Review.

PMID:
26261064
7.

Efficacy of Kisspeptin-54 to Trigger Oocyte Maturation in Women at High Risk of Ovarian Hyperstimulation Syndrome (OHSS) During In Vitro Fertilization (IVF) Therapy.

Abbara A, Jayasena CN, Christopoulos G, Narayanaswamy S, Izzi-Engbeaya C, Nijher GM, Comninos AN, Peters D, Buckley A, Ratnasabapathy R, Prague JK, Salim R, Lavery SA, Bloom SR, Szigeti M, Ashby DA, Trew GH, Dhillo WS.

J Clin Endocrinol Metab. 2015 Sep;100(9):3322-31. doi: 10.1210/jc.2015-2332. Epub 2015 Jul 20.

8.

A Bump on the Knee.

Khodaee M, Ashby D.

Am Fam Physician. 2015 Jul 15;92(2):149-50. No abstract available.

PMID:
26176374
9.

Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial.

Alton EW, Armstrong DK, Ashby D, Bayfield KJ, Bilton D, Bloomfield EV, Boyd AC, Brand J, Buchan R, Calcedo R, Carvelli P, Chan M, Cheng SH, Collie DD, Cunningham S, Davidson HE, Davies G, Davies JC, Davies LA, Dewar MH, Doherty A, Donovan J, Dwyer NS, Elgmati HI, Featherstone RF, Gavino J, Gea-Sorli S, Geddes DM, Gibson JS, Gill DR, Greening AP, Griesenbach U, Hansell DM, Harman K, Higgins TE, Hodges SL, Hyde SC, Hyndman L, Innes JA, Jacob J, Jones N, Keogh BF, Limberis MP, Lloyd-Evans P, Maclean AW, Manvell MC, McCormick D, McGovern M, McLachlan G, Meng C, Montero MA, Milligan H, Moyce LJ, Murray GD, Nicholson AG, Osadolor T, Parra-Leiton J, Porteous DJ, Pringle IA, Punch EK, Pytel KM, Quittner AL, Rivellini G, Saunders CJ, Scheule RK, Sheard S, Simmonds NJ, Smith K, Smith SN, Soussi N, Soussi S, Spearing EJ, Stevenson BJ, Sumner-Jones SG, Turkkila M, Ureta RP, Waller MD, Wasowicz MY, Wilson JM, Wolstenholme-Hogg P; UK Cystic Fibrosis Gene Therapy Consortium.

Lancet Respir Med. 2015 Sep;3(9):684-91. doi: 10.1016/S2213-2600(15)00245-3. Epub 2015 Jul 3. Erratum in: Lancet Respir Med. 2015 Sep;3(9):e33.

10.

Use of an uncensored primary outcome in a catheter design trial?

Ashby DR, Corbett RW.

Am J Kidney Dis. 2015 Jul;66(1):170. doi: 10.1053/j.ajkd.2015.03.037. Epub 2015 May 19. No abstract available.

PMID:
26002294
11.

Hepcidin-25 in diabetic chronic kidney disease is predictive for mortality and progression to end stage renal disease.

Wagner M, Ashby DR, Kurtz C, Alam A, Busbridge M, Raff U, Zimmermann J, Heuschmann PU, Wanner C, Schramm L.

PLoS One. 2015 Apr 20;10(4):e0123072. doi: 10.1371/journal.pone.0123072. eCollection 2015.

12.

Prokinetics prescribing in paediatrics: evidence on cisapride, domperidone, and metoclopramide.

Mt-Isa S, Tomlin S, Sutcliffe A, Underwood M, Williamson P, Croft NM, Ashby D.

J Pediatr Gastroenterol Nutr. 2015 Apr;60(4):508-14. doi: 10.1097/MPG.0000000000000657.

PMID:
25825854
13.

A Bayesian approach to probabilistic sensitivity analysis in structured benefit-risk assessment.

Waddingham E, Mt-Isa S, Nixon R, Ashby D.

Biom J. 2016 Jan;58(1):28-42. doi: 10.1002/bimj.201300254. Epub 2015 Jan 28.

PMID:
25631038
14.

Ursodeoxycholic acid for cystic fibrosis-related liver disease.

Cheng K, Ashby D, Smyth RL.

Cochrane Database Syst Rev. 2014 Dec 15;12:CD000222. doi: 10.1002/14651858.CD000222.pub3. Review.

PMID:
25501301
15.

Effects of targeted delivery of propionate to the human colon on appetite regulation, body weight maintenance and adiposity in overweight adults.

Chambers ES, Viardot A, Psichas A, Morrison DJ, Murphy KG, Zac-Varghese SE, MacDougall K, Preston T, Tedford C, Finlayson GS, Blundell JE, Bell JD, Thomas EL, Mt-Isa S, Ashby D, Gibson GR, Kolida S, Dhillo WS, Bloom SR, Morley W, Clegg S, Frost G.

Gut. 2015 Nov;64(11):1744-54. doi: 10.1136/gutjnl-2014-307913. Epub 2014 Dec 10.

16.

Alternatives to arteriovenous fistulas.

Corbett RW, Ashby DR, Duncan ND.

BMJ. 2014 Dec 2;349:g7249. doi: 10.1136/bmj.g7249. No abstract available.

PMID:
25466719
17.

Stability of avoidance behaviour following repeated intermittent treatment with clozapine, olanzapine or D,L-govadine.

Ashby DM, Lapish CC, Phillips AG.

Behav Pharmacol. 2015 Feb;26(1-2):133-8. doi: 10.1097/FBP.0000000000000097.

PMID:
25325293
18.

Benefit-risk assessment in a post-market setting: a case study integrating real-life experience into benefit-risk methodology.

Hallgreen CE, van den Ham HA, Mt-Isa S, Ashworth S, Hermann R, Hobbiger S, Luciani D, Micaleff A, Thomson A, Wang N, van Staa TP, Downey G, Hirsch I, Hockley K, Juhaeri J, Metcalf M, Mwangi J, Nixon R, Peters R, Stoeckert I, Waddingham E, Tzoulaki I, Ashby D, Wise L.

Pharmacoepidemiol Drug Saf. 2014 Sep;23(9):974-83. doi: 10.1002/pds.3676. Epub 2014 Jul 5.

PMID:
25043919
19.

Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization.

Jayasena CN, Abbara A, Comninos AN, Nijher GM, Christopoulos G, Narayanaswamy S, Izzi-Engbeaya C, Sridharan M, Mason AJ, Warwick J, Ashby D, Ghatei MA, Bloom SR, Carby A, Trew GH, Dhillo WS.

J Clin Invest. 2014 Aug;124(8):3667-77. doi: 10.1172/JCI75730. Epub 2014 Jul 18.

20.

Protocol for a randomised controlled trial of VAsopressin versus Noradrenaline as Initial therapy in Septic sHock (VANISH).

Gordon AC, Mason AJ, Perkins GD, Ashby D, Brett SJ.

BMJ Open. 2014 Jul 3;4(7):e005866. doi: 10.1136/bmjopen-2014-005866.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk